By Clinical Research Staff 

June 30, 2026 | The Ellison Medical Institute enters an exclusive license with UniQuest; TrialAssure and Cancer Research UK’s Centre for Drug Development announce new partnership; EndoDNA launches BIOS, a clinical decision-support; and more. 

The U.S. Department of Health and Human Services (HHS) announced a coordinated department-wide effort to strengthen America’s leadership in clinical research, accelerate the development of lifesaving treatments, and ensure that patients have access to the most innovative therapies in the world. The HHS is taking decisive action to reverse that trend and make the U.S. the preferred destination for clinical research and medical discovery. Press release. 

Clinilabs announced a new partnership with Rutgers Health, School of Health Professions, Master of Science, Clinical Research Management program (MS CRM), reflecting the company’s ongoing commitment to advancing scientific education and strengthening the future clinical research workforce. The educational affiliation between Clinilabs and Rutgers University is structured to provide graduate-level students with hands-on, applied clinical research experience (CRE) within an active clinical research environment. Through this partnership, MS CRM students will complete precepted clinical rotations at Clinilabs, working on real-world clinical operations, quality, data, and research support projects aligned with both academic objectives and Clinilabs’ operational protocols. Press release.

NVIDIA announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era. Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery. It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions. Press release.

Genialis announced Genialis BioBridge to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into biomarker-ready assets for Western trials and regulatory submissions. The global drug development landscape has shifted with many innovative oncology therapies now being discovered and clinically validated first in China before being licensed for development in North America and Europe. However, there are still regulatory and biological challenges. Clinical efficacy signals, biomarker strategies, and patient response patterns observed in Chinese trials may not translate directly to Western patient populations. BioBridge is powered by the Genialis Supermodel, a large molecular model of cancer biology pre-trained on more than one billion RNA-sequencing data points from globally diverse patients. BioBridge uses clinical and molecular data to estimate responder populations in diverse global regions. This allows pharma sponsors to anticipate differences in efficacy signals from Chinese trial results. Press release.

Medidata introduced its Academic Site Advisory Board. The launch of the Academic Site Advisory Board marks a major strategic expansion of Medidata's industry-leading Sites Insights Program. This initiative is purpose-built to address the unique operational realities of clinical sites by driving new solutions that eliminate workflow bottlenecks, deliver true financial transparency, and optimize the execution of decentralized and hybrid clinical trials. Press release.

ICON has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three years. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterprise-grade cloud, data and AI infrastructure to further scale Orbis, ICON’s secure, governed agentic AI platform. Through Orbis, ICON is building an intelligence layer that connects expertise, data, and AI across the trial lifecycle. By combining frontier model capabilities with ICON's operational expertise, it has significant impacts on the trial lifecycle through: accelerating study design, streamlining operational execution, enhancing patient and site engagement, and strengthening decision‑making. Press release.

The Ellison Medical Institute (EMI) has entered an exclusive license with UniQuest, the commercialization company of The University of Queensland, to advance QED-203, a novel small molecule therapeutic designed to address significant unmet needs in metastatic castration-resistant prostate cancer, toward first-in-human studies in early 2027. Under the agreement, EMI will lead the continued development of QED-203, applying its integrated capabilities across AI-enabled discovery, translational research, human-relevant preclinical models, and in-house clinical expertise to prepare the program for clinical evaluation. Press release.

Hartwig Medical Foundation and Ultima Genomics expanded their strategic collaboration, marked by Hartwig's adoption of the new Ultima UG200, Ultima's second-generation sequencing system. The agreement builds on the organization's existing work with Ultima's technology and is designed to accelerate Hartwig's mission to make whole-genome sequencing more accessible, scalable, and clinically actionable for oncology patients. Press release.

The University of Texas MD Anderson Cancer Center joined a global consortium dedicated to accelerating the elimination of cervical cancer worldwide. The collaboration agreement with the Elimination Partnership in Cervical Cancer (EPICC) expands UT MD Anderson’s global oncology efforts, further strengthening its commitment to advancing cancer prevention and control in medically underserved regions. The EPICC program, led by the University of Sydney in collaboration with a consortium of local and global partners, is funded by the Australian Government and the Minderoo Foundation. The initiative works to improve sustainable health outcomes and equity and to support national cervical cancer elimination strategies around the world. The program provides a mix of technical, policy, and implementation support for vaccination, screening, and treatment in more than nine countries. Press release.

When a person loses a limb, a prosthesis often can help restore a significant degree of mobility. But when movement or communication is impaired by a neurological condition such as ALS, spinal cord injury, or stroke, there currently are few options for the affected individual. To address this challenge, Baylor College of Medicine, in collaboration with Rice University, joined BrainGate, a consortium of universities and academic medical centers working on creating brain-computer interface (BCI) technologies. BCIs are systems that link the brain with an external system such as a robotic arm or a speaker. They allow the individual to move the arm or speak just by thinking about the action, thereby restoring communication, mobility, and independence. BCM and Rice will be just the sixth team in the consortium and the only team in Texas. Press release.